Researchers at MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
